Quick Facts: Therapeutic Domains

• Hypertension (High Blood Pressure): Manages elevated blood pressure in adults and pediatric patients aged 6 years and older.
• Angina: Indicated for the symptomatic management of chronic stable angina and confirmed or suspected vasospastic (Prinzmetal’s or variant) angina.
• Coronary Artery Disease (CAD): Used in patients with recently documented CAD to support the reduction of the risk of hospitalization for angina and coronary revascularization procedures.

What Stadovas Treats: Main Uses and Benefits

Stadovas is a prescription medication utilized in the management of several cardiovascular conditions. Its primary approved therapeutic domain is the treatment of hypertension, also known as high blood pressure, in adults and in children 6 years of age and older. Lowering blood pressure is a key step in overall cardiovascular risk management and may contribute to the reduction of the risk of fatal and nonfatal cardiovascular events, such as strokes and myocardial infarctions.

The medication is also indicated for the symptomatic treatment of chronic stable angina (chest pain). Furthermore, it is a therapeutic option for confirmed or suspected vasospastic angina.

In patients with angiographically documented coronary artery disease who do not have heart failure or an ejection fraction below 40%, Stadovas is used to support the reduction of the risk of hospitalization for angina and to lessen the need for coronary revascularization procedures. For these indications, it may be used alone or in combination with other antianginal or antihypertensive agents, as determined by a qualified healthcare professional.

Regulatory References

1. FDA therapeutic overview

Who Can and Cannot Use Stadovas? — Official Regulatory Information

Stadovas (a combination of amlodipine and atorvastatin) is subject to strict eligibility rules defined in regulatory labeling.

Contraindications (Must Not Use)

The medicine is formally contraindicated for patients with:

• Hypersensitivity to amlodipine, atorvastatin, or any related components.
• Active Liver Disease or unexplained, persistent elevations in liver enzymes.
• Pregnancy or in women who may become pregnant (due to the risk of fetal harm from the atorvastatin component).

Special Population Restrictions

• Lactation: Use is not recommended while breastfeeding, as the drug's components may pass into breast milk.
• Pediatric Use: Safety and effectiveness for the combination product are generally not established in the overall pediatric population. Use is typically limited to children 10 years and older for specific indications of the individual components.
• Comorbidities: Caution and close monitoring are required for patients with predisposing factors for muscle toxicity, such as uncontrolled hypothyroidism, severe renal impairment, or being 65 years or older. Therapy must also be temporarily discontinued in patients with acute conditions like sepsis or major trauma.

Stadovas, which contains the active substance Amlodipine, is subject to interactions primarily related to metabolism by the CYP3A4 enzyme and additive effects on blood pressure. The official regulatory documents provide specific constraints for co-administration with certain products and medicines.

Documented Interaction Constraints

Restrictions and Special Notes

• Simvastatin Dose Limit: The maximum daily dose of Simvastatin must not exceed 20 mg when co-administered with Stadovas due to the increased exposure of Simvastatin.
• Population Note: The effects of CYP3A4 inhibitors and inducers on Stadovas exposure may be more pronounced in elderly patients and in those with severe hepatic impairment, owing to the drug's reduced clearance in these populations.

The mechanism of action for Stadovas (Amlodipine) is initiated by its function as an antagonist at the voltage-dependent L-type calcium channels ( Cav1.2). These channels are primarily targeted in the smooth muscle cells of peripheral arteries. By physically blocking the channel, the drug prevents the influx of extracellular calcium ions ( Ca^2+), which are critical molecular triggers for cellular contraction. This Ca^2+ reduction interrupts the biochemical cascade—specifically inhibiting Myosin Light-Chain Kinase (MLCK) activation—leading to the prolonged relaxation of arterial smooth muscle (vasodilation). This vasoselective effect fundamentally reduces the peripheral vascular resistance (PVR) throughout the systemic circulation, decreasing the external workload (afterload) on the heart. The mechanism is characterized by a slow rate of association and dissociation from the calcium channel receptor, which ensures a sustained 24-hour effect but dictates a gradual onset of maximum physiological adjustment. The mechanism is not characterized by the rapid onset kinetics required for acute physiological response.

How to Use Stadovas: Administration Guidelines

Stadovas is an oral medication, provided as a tablet that is designed to be taken once daily. The tablet may be administered at the same time each day, with or without food.

Dosing and Titration Schedule

For adults across all approved uses, the usual initial oral dose is 5 mg once daily. Dosage adjustments, if required, should generally be performed slowly over an interval of 7 to 14 days to allow the response to each dose level to be fully assessed. The maximum recommended daily dose for adults is 10 mg.

Administration for Specific Patient Groups

For small, frail, or older adults, as well as patients with hepatic insufficiency, a lower initial oral dose of 2.5 mg once daily is recommended. Normal dosage regimens are recommended for patients with renal impairment, as dose changes are not correlated with the degree of kidney function decline. In the pediatric population (6 to 17 years) for hypertension, the starting dose is 2.5 mg, with the maximum daily dose being 5 mg.

If a dose is missed, it should be taken as soon as possible, but only if the next scheduled dose is more than 12 hours away. Patients are instructed not to double the subsequent dose to compensate for the skipped one.

Research Evidence / Overview of studies for Stadovas

Evidence for use in Hypertension (High Blood Pressure)

Research examining Stadovas was studied for high blood pressure using several large studies, including randomized trials where the medicine was compared against a placebo (an inactive substance) or against other types of blood pressure medications. These studies monitored adult participants with mild to moderate high blood pressure, sometimes over periods of several years.

Research examined changes in Systolic and Diastolic Blood Pressure measurements over 24 hours. The trials described measured changes in blood pressure compared to placebo. Long-term studies monitored large groups to observe patterns related to the incidence of major cardiovascular events, such as stroke or myocardial infarction. Comparative evidence examined patterns in incidence of heart failure in trials against certain other antihypertensive drug classes.

Evidence for use in Angina (Chest Pain)

Stadovas was studied for both chronic stable angina (chest pain that occurs with effort) and vasospastic angina (a type of chest pain that can happen at rest). These were often short-term, placebo-controlled clinical trials exploring short-term symptom changes. Studies monitored patient-reported outcomes describing perceived discomfort and outcomes related to functional capacity.

Evidence for use in Coronary Artery Disease (CAD)

Evidence for use in Coronary Artery Disease (CAD) was derived from large trials of patients who already had angiographically documented CAD. These research settings were designed to monitor the occurrence of certain major events, such as hospitalizations for unstable angina and the need for a coronary revascularization procedure. The trials reported patterns related to the incidence of certain procedural endpoints, including hospitalizations for unstable angina and the need for revascularization procedures when compared to placebo. The data show patterns related to procedural outcomes in highly selected populations.

Long-Term Studies and Durability of Evidence

Research has explored the effects of Stadovas over defined time intervals, including long-term follow-up that lasted several years in some large trials. Evidence from these settings suggests patterns related to maintaining stable blood pressure control over several years. However, long-term effects are not fully established for all possible outcomes, and data are still emerging regarding the durability of specific functional outcomes beyond the typical study duration.

Research Gaps and Areas of Uncertainty

The specific influence on the progression of the underlying artery disease itself remains an area where research is still developing, as primary measures did not describe a consistent change in the progression of the blockages. Comparative evidence is lacking for the isolated active component (S-isomer) in large-scale outcomes trials. Study results reflect the specific conditions under which they were conducted, and findings describe group patterns, not personal outcomes.

Key Studies & References

1. Amlodipine Besylate Tablet - Official FDA Label/DailyMed Monograph
2. Major Outcomes in High-Risk Hypertensive Patients Randomly Assigned to Initial Treatment With Chlorthalidone, Amlodipine, or Lisinopril: The ALLHAT Randomized Trial

Common questions about Stadovas (FAQ)

Q: What is the main medical condition Stadovas is officially used to treat?

Official indications state that this combination medicine is approved to treat multiple conditions. It is used for high blood pressure (hypertension) and certain heart conditions (such as angina or coronary artery disease). Additionally, it is indicated to lower high cholesterol and fat levels, a condition known as hyperlipidemia.

Q: Is Stadovas a brand name or the generic name for the medicine?

The name Stadovas is a brand name assigned to the medication. The active substances contained within the drug, Amlodipine and Atorvastatin, represent the generic names of the components. Regulatory documents describe the product using both the brand name and the generic names of its active ingredients.

Q: Does Stadovas interact with common over-the-counter pain relievers?

Official prescribing information indicates that Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as ibuprofen or naproxen, may reduce the blood pressure-lowering effect of the medicine when used long-term. There are no notable interactions specifically documented with acetaminophen. Official documents recommend consulting a healthcare professional regarding any over-the-counter medications.

Q: Does taking Stadovas affect the results of routine lab blood tests?

Yes, the active ingredients in Stadovas can cause changes in certain laboratory tests. Official regulatory documents recommend monitoring liver enzymes before and during treatment because of the Atorvastatin component. Testing for muscle breakdown indicators, known as CK levels, may also be warranted if specific symptoms occur.

Q: Does Stadovas have known effects on body weight (gain or loss)?

Regulatory safety documents report that changes in body weight, which can include both weight gain and weight decrease, have been noted as uncommon side effects. These reports describe patterns observed across patient groups in clinical settings.

Q: Can Stadovas affect sleep patterns or cause insomnia?

Yes, official product information indicates that changes to sleep patterns are possible. Insomnia (trouble sleeping), as well as nervousness and abnormal dreams, have been reported as uncommon side effects in clinical trials.

Q: Does Stadovas have a black box warning listed in official documents?

No, a Black Box Warning is a specific, strict safety communication placed by the FDA on certain medicines that carry serious risks. The official FDA Prescribing Information for Stadovas does not carry this designation.

Q: Is it safe to take Stadovas with common vitamin supplements?

Regulatory documents describe the importance of discussing all supplements, including vitamins, with a healthcare professional before starting treatment. While specific vitamins are not universally listed as interacting substances, potential interactions are possible with any co-administered products.

Q: What is the typical duration of Stadovas treatment for the conditions it addresses?

This medicine is officially indicated for the treatment of chronic conditions, such as high blood pressure and high cholesterol. This means that the treatment is typically continuous and long-term, and is typically continued as directed by a healthcare professional.

Q: If a person stops taking Stadovas, how long does the drug typically remain in the system?

The time the drug remains in the system is determined by the half-life of the active ingredients. The half-life of Amlodipine, one of the components, ranges from 30 to 50 hours. This measure describes the time needed for half of the substance to be eliminated from the body.

Q: What is the history of Stadovas's development and approval?

The combination product containing both active ingredients received its official approval from the Food and Drug Administration (FDA) on January 30, 2004. This information is found in the drug's regulatory history.

Q: Is Stadovas classified as a controlled substance?

No, this medicine is not classified as a controlled substance under the Controlled Substances Act (CSA) in the United States. This legal classification is typically applied to drugs that have an accepted medical use but carry a higher risk of potential abuse.

Q: Does the active ingredient in Stadovas contain a steroid component?

No, the official composition of the medicine does not include any steroid components. The two active ingredients are Amlodipine, a calcium channel blocker, and Atorvastatin, which belongs to the statin class of cholesterol-lowering medicines.

Q: Is Stadovas known to carry a risk of dependency or addiction?

Official regulatory bodies classify drugs with a known risk of dependency or abuse as controlled substances. Because Stadovas is not classified as a controlled substance, it is not identified by regulators as having this type of abuse potential.

How to Store and Dispose of Stadovas

Official regulatory documents define specific storage and disposal requirements for Stadovas (Amlodipine Besylate) tablets.

Storage Requirements

Stadovas must be stored at Controlled Room Temperature (CRT), which is 20 C to 25 C (68 F to 77 F). The product must be kept in its original, tightly closed container and protected from both moisture and light. It is explicitly stated that the tablets must not be frozen. The medicine must also be stored safely out of the reach and sight of children.

Disposal Instructions

Unused or expired tablets should be disposed of according to local regulations, ideally through a certified drug take-back program. If no take-back program is available, the tablets must be mixed with an undesirable substance, placed in a sealed bag, and discarded in the household trash. The official instructions mandate that the medicine must not be flushed down a toilet or poured down a sink.